L De Marinis
Overview
Explore the profile of L De Marinis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
154
Citations
1048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chiloiro S, Giampietro A, Raffaelli M, DAmato G, Bima C, Lauretti L, et al.
Endocrine
. 2019 Oct;
66(3):642-649.
PMID: 31583577
Introduction: Hypercortisolism requires a prompt therapeutic management to reduce the risk of development of a potential fatal emergency. A synchronous bilateral adrenalectomy (SBA) is effective in recovering hypercortisolism. However, specific...
2.
Bima C, Chiloiro S, Mormando M, Piacentini S, Bracaccia E, Giampietro A, et al.
Expert Rev Endocrinol Metab
. 2018 Jul;
11(3):263-270.
PMID: 30058934
Acromegaly, caused in most cases by Growth Hormone (GH)-secreting pituitary adenomas, is characterized by increased skeletal growth and enlargement of the soft tissue, because GH and its effector Insulin-like Growth...
3.
Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, et al.
J Endocrinol Invest
. 2017 Dec;
41(2):267.
PMID: 29285678
Unfortunately, in page 584, second column, the first sentence under the heading "Type of switch" has been published incorrectly. The complete correct sentence is given below.
4.
Ragonese M, Grottoli S, Maffei P, Alibrandi A, Ambrosio M, Arnaldi G, et al.
J Endocrinol Invest
. 2017 Oct;
41(5):575-581.
PMID: 29080965
Purpose: Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study....
5.
Chiloiro S, Mormando M, Bianchi A, Giampietro A, Milardi D, Bima C, et al.
Endocrine
. 2017 Aug;
59(2):449-453.
PMID: 28836162
Introduction: Skeletal fragility with high risk of vertebral fractures is an emerging complication of acromegaly in close relationship with duration of active disease. The aim of this cross-sectional study was...
6.
Chiloiro S, Giampietro A, Bianchi A, Tartaglione T, Capobianco A, Anile C, et al.
Eur J Endocrinol
. 2017 Aug;
177(6):R275-R285.
PMID: 28780516
Primary empty sella (PES) is characterized by the herniation of the subarachnoid space within the sella, which is often associated with variable degrees of flattening of the pituitary gland in...
7.
Chiloiro S, Lanza F, Bianchi A, Schinzari G, Brizi M, Giampietro A, et al.
Endocrine
. 2017 Jun;
60(2):362-367.
PMID: 28567607
Purpose: Multiple endocrine neoplasia type 1 (MEN1) is an inherited endocrine neoplastic syndrome associated with a greater risk of endocrine tumor development like pancreatic neuroendocrine tumors (p-NET), with different clinical...
8.
Giustina A, Arnaldi G, Bogazzi F, Cannavo S, Colao A, De Marinis L, et al.
J Endocrinol Invest
. 2017 Feb;
40(6):577-589.
PMID: 28176221
Background: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical...
9.
Mormando M, Chiloiro S, Bianchi A, Giampietro A, Angelini F, Tartaglione L, et al.
Clin Endocrinol (Oxf)
. 2016 Jul;
85(5):717-724.
PMID: 27437620
Introduction: Growth hormone deficiency is considered the most important factor determining skeletal fragility in hypopituitary patients. Osteoblasts and chondrocytes express growth hormone (GH) receptor. Two GH receptor isoforms (GHRi) have...
10.
Chiloiro S, Giampietro A, Bianchi A, De Marinis L
Endocrine
. 2015 Dec;
53(3):636-42.
PMID: 26701679
Intracranial teratomas are rare and comprise about 0.5 % of all intracranial tumours. Actually, a total of 15 cases of sellar-suprasellar teratoma have been described in the last 24 years....